Biocept

We are dedicated to helping physicians improve outcomes for patients with metastatic cancer by delivering advanced diagnostic testing solutions.

[Biocept @Biocept]

In case you haven’t already, check out Biocept on our other social media platforms! #GetCancerAnswers

LinkedIn:
https://t.co/qeCkWkYQmu
Facebook:
https://t.co/MSD7wzvPjR
Instagram:
https://t.co/iDE02zWK5w

[Biocept @Biocept]

The San Diego forecast last week was 100% chance of ugly sweater weather. Everyone looked snow good!

[Biocept @Biocept]

We’re simply having a wonderful festive thyme! Thanks to all those who made our space feel jolly during our holiday workplace decorating contest and congratulations to our winners! (Part 3)

[Biocept @Biocept]

We’re simply having a wonderful festive thyme! Thanks to all those who made our space feel jolly during our holiday workplace decorating contest and congratulations to our winners! (Part 2)

[Biocept @Biocept]

We’re simply having a wonderful festive thyme! Thanks to all those who made our space feel jolly during our holiday workplace decorating contest and congratulations to our winners! (Part 1)

[Biocept @Biocept]

Happy Holidays from the Biocept team! We wish you and your family all the best this holiday season and upcoming year! #CNSide #GetCancerAnswers

[Biocept @Biocept]

“When you’re diagnosed with a brain tumor, it’s not just a chapter in your life.” – Dan Zappa

Together, let’s continue to invest in hope for patients with LM and brain tumors. Visit https://t.co/g12YpfLytr to donate this holiday season.

@theABTA #GetCancerAnswers

[Biocept @Biocept]

For more information on how to order CNSide™ Next-Generation Sequencing testing on cerebrospinal fluid, please visit https://t.co/J7sAWVK0Sh.

[Biocept @Biocept]

Today is #GivingTuesday. Together, let’s invest in hope for patients with leptomeningeal metastasis and brain tumors.

In the spirit of holiday giving, donate now to @theABTA: https://t.co/EBVEG4XgZj

#GetCancerAnswers

[Biocept @Biocept]

Visit Biocept’s booth (#512) at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology and learn about the clinical poster on mutant p53 positive glioblastoma cells being presented on Friday, 11/18 from 7:30-9:30 PM ET. #CNSide #GetCancerAnswers #SNO2022

[Biocept @Biocept]

Visit Biocept’s booth (#512) at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology and learn about the PPTID clinical poster being presented on Friday, 11/18 from 7:30-9:30 PM ET. @NeuroOnc #CNSide #GetCancerAnswers #SNO2022

[Biocept @Biocept]

Visit Biocept’s booth (#512) at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology and learn about the HER2 Flip clinical poster being presented on Friday, 11/18 from 7:30-9:30 PM ET. @NeuroOnc #GetCancerAnswers #SNO2022

[Biocept @Biocept]

#FlashbackFriday to our Biocept luncheon with @Duffsdoggz to celebrate the @Padres advancing in the playoffs! Let’s go Padres!

[Biocept @Biocept]

#InTheNews: Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System

Learn more: https://t.co/3GfZQHcixA

#CNSide #GetCancerAnswers

[Biocept @Biocept]

Join our CNSide webinar on October 14th at 1:00pm ET, featuring key opinion leaders Priya U. Kumthekar, MD and Seema A. Nagpal, MD.

Register here: https://t.co/Umx8YAAmGI

#CNSide #GetCancerAnswers

[Biocept @Biocept]

Did you know? Biocept initiated a clinical trial, the FORESEE Study, for patients with breast or non-small cell lung cancer (NSCLC) who have suspected or confirmed leptomeningeal metastases (LM).

Learn more: https://t.co/WJm68JyKre

#CNSide #GetCancerAnswers #FORESEEStudy

[Biocept @Biocept]

Science and creativity go hand in hand. It’s no surprise our Biocept team can paint like Van Gogh. 😊

#teambuilding #ThrowbackThursday

[Biocept @Biocept]

Today is Stand Up To Cancer Day. Join us in bringing awareness. We’re stronger together.

#StandUpToCancer #GetCancerAnswers #CNSide

[Biocept @Biocept]

@theABTA is hosting a free, virtual meeting for brain tumor patients, caregivers, families, and survivors on September 9-10th. Leading experts in the field will share the latest advances. The final day to register is September 7th.

Learn more here: https://t.co/z4x5JTJ5LA

[Biocept @Biocept]

#IntheNews: Plus Therapeutics Awarded $17.6 Million from State of Texas. The funding will support the ReSPECT-LM Study and development of Rhenium-186 NanoLiposome (186RNL) for leptomeningeal metastases. Learn more on @plustxinc:
https://t.co/iphCxfhYUI

#ClinicalTrial #CNSide